Indivior Pharmaceuticals Inc
INDVHealthcare|Drug Manufacturers - Specialty & Generic|USA
$40.50
-0.80 (-1.94%)
Earnings Power
$19.49
Clinical Trials (58)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04060654 SUBLOCADE Rapid Initiation Extension Study | Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate | P4 | Completed | 17 | Open-label | Sublocade |
| NCT05704543 Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations | Opioid Use Disorder | P4 | Completed | 132 | RCT, Open-label | Buprenorphine Extended-Release Injection |
| NCT04995029 Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users | Moderate to Severe Opioid-use Disorder | P4 | Completed | 785 | RCT, Double-blind | Transmucosal Buprenorphine, Extended-release Buprenorphine |
| NCT01846455 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects | Hepatic Failure, Hepatic Impairment | P4 | Completed | 43 | Open-label | 2.0mg Buprenorphine/0.5mg Naloxone, Promethazine |
| NCT00955162 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") | Opioid Dependency | P4 | Completed | 270 | RCT, Open-label | Buprenorphine (Subutex), Buprenorphine/naloxone (Suboxone) |
| NCT00901875 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan | Opiate Dependence | P4 | Completed | 127 | RCT, Open-label | Buprenorphine + naloxone (Suboxone), Buprenorphine + naloxone (Suboxone) |
| NCT00279565 Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED) | Hepatitis C, Chronic | P4 | Terminated | 128 | RCT, Open-label | buprenorphine, methadone, pegylated interferon alfa-2b plus ribavirin |
| NCT00605033 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) | Opiate Dependence, Drug Dependence | P4 | Completed | 241 | RCT, Double-blind | Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484, Subutex, Buprenorphine Hydrochloride, SCH 28444 |
| NCT02038790 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population | Opioid Dependence | P4 | Completed | 33 | RCT, Open-label | Suboxone Sublingual Film, Zubsolv sublingual tablets |
| NCT03978832 Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone | Schizophrenia | P4 | Completed | 69 | Open-label | PERSERIS, Risperidone |
| NCT00684073 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) | Opiate-related Disorders, Opiate Dependence | P4 | Completed | 60 | Open-label | buprenorphine, buprenorphine/naloxone |
| NCT03993392 SUBLOCADE Rapid Initiation Study | Opioid-use Disorder | P4 | Completed | 26 | Open-label | TM buprenorphine, SUBLOCADE |
| NCT02203838 Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia | Schizophrenia | P3 | Completed | 500 | Open-label | RBP-7000 |
| NCT02510014 Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder | Opioid Use Disorder, Opioid-related Disorders | P3 | Completed | 775 | Open-label | SUBOXONE sublingual film, RBP-6000 |
| NCT01760473 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone | Heroin Dependence | P3 | Completed | 27 | RCT, Double-blind | Intranasal challenge drug |
| NCT02109562 Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients | Schizophrenia | P3 | Completed | 354 | RCT, Double-blind | RBP-7000, Placebo, Risperidone |
| NCT04523792 Virginia Opioid Treatment-Emergency Department | Opioid Use Disorder | P3 | Withdrawn | — | Open-label | SUBLOCADE |
| NCT03818399 Virginia Opioid Overdose Treatment InitiatVE | Opioid Use Disorder | P3 | Terminated | 19 | Open-label | SUBLOCADE |
| NCT02896296 Open-Label Treatment Extension Study | Opioid Use Disorder, Opioid-related Disorders | P3 | Completed | 208 | Open-label | RBP-6000 |
| NCT02357901 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine | Opioid Dependence, Opioid Related Disorders | P3 | Completed | 665 | RCT, Double-blind | SUBOXONE, RBP-6000, Placebo |
| NCT01582347 Transfer of Subjects From Subutex/Suboxone to RBP-6300 | Opioid Related Disorder | P2 | Completed | 143 | RCT, Double-blind | RBP-6300, Subutex®/Suboxone®, Placebo for RBP-6300, Placebo for Subutex®/Suboxone® |
| NCT02511886 A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder | Alcohol Use Disorder | P2 | Completed | 18 | RCT, Double-blind | Arbaclofen Placarbil, Placebo |
| NCT06384157 Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder | Opioid Use Disorder | P2 | Completed | 300 | RCT, Double-blind | INDV-2000 |
| NCT01846481 A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse | Opioid Dependence, Opioid Related Disorders | P2 | Completed | 40 | RCT, Double-blind | RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg |
| NCT01738503 Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects | Opioid Related Disorder | P2 | Completed | 124 | Open-label | RBP-6000, Subutex |
| NCT06576843 INDV-6001 Multiple-Dose Pharmacokinetic Study | Moderate to Severe Opioid Use Disorder | P2 | Completed | 123 | Single-blind | INDV-6001, Suboxone, Sublocade |
| NCT01075971 Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED) | Opioid Dependency | P2 | Completed | 52 | Open-label | Buprenorphine hydrochloride marketed sublingual tablet (Subutex), Buprenorphine hydrochloride fast dissolving tablet (FDT) |
| NCT01677377 Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy | Schizophrenia | P2 | Completed | 45 | Open-label | Risperidone, RBP-7000 |
| NCT00838396 A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease | GERD | P2 | Completed | 58 | RCT, Double-blind | XP19986 CR, Placebo for XP19986 CR |
| NCT00637000 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone | Opioid-related Disorders | P2 | Completed | 38 | RCT, Double-blind | Buprenorphine soluble film, Buprenorphine/naloxone film strip, Placebo |
| NCT00640835 Safety and Tolerability of Buprenorphine/Naloxone Film Strips | Opioid-Related Disorders | P2 | Completed | 382 | RCT, Open-label | Buprenorphine/naloxone Film Strip, Buprenorphine/naloxone Film Strip |
| NCT02044094 Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder | Opioid Use Disorder | P2 | Completed | 39 | Open-label | Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo |
| NCT03715634 Study of a Novel Subcutaneous Depot Formulation of Buprenorphine | Opioid-use Disorder | P1 | Completed | 12 | RCT, Single-blind | INDV-6200, Placebo, SL Buprenorphine, Nalorex |
| NCT03058237 A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 40 | RCT, Open-label | Arbaclofen Placarbil SR, Arbaclofen Placarbil MR Prototype A, Arbaclofen Placarbil MR Prototype B, Arbaclofen Placarbil IR |
| NCT03002961 Single Ascending Dose Study of RBP-6000 | Opioid Use Disorder | P1 | Completed | 48 | Open-label | RBP-6000, Suboxone |
| NCT02768649 Single Ascending Dose Study of RBP-7000 | Schizophrenia | P1 | Completed | 45 | Open-label | RBP-7000, risperidone |
| NCT05974046 Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants | Opioid Use Disorder | P1 | Completed | 7 | Open-label | [14C]IDV184001AN |
| NCT02765555 First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 | Schizophrenia | P1 | Completed | 12 | Open-label | RBP-7000 |
| NCT02687984 PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia | Schizophrenia | P1 | Completed | 44 | RCT, Open-label | RBP-7000 |
| NCT04976855 Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder | Healthy Volunteer, Opioid-use Disorder | P1 | Completed | 64 | RCT, Double-blind | INDV-2000, Placebo, SUBOXONE® sublingual film |
| NCT04413552 INDV-2000 First in Human | Opioid Dependence | P1 | Completed | 73 | RCT, Double-blind | INDV-2000, Placebo |
| NCT02765867 Single-dose, Study of RBP-6000 in Opioid Dependent Individuals | Opioid Use Disorder | P1 | Completed | 18 | Open-label | RBP-6000 |
| NCT05694533 Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults | Healthy | P1 | Completed | 20 | Open-label | INDV-2000, Midazolam |
| NCT03747341 Buprenorphine-Fentanyl Interaction Study | Healthy, Opioid Use | P1 | Completed | 22 | RCT, Single-blind | Buprenorphine Injectable Solution - Part A, Placebo - Parts A + B, Fentanyl - Part A, Ondansetron - Parts A + B, Buprenorphine Injectable Solution - Part B, Fentanyl - Part B, Oxycodone - Part B |
| NCT02559973 Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder | Opioid Use Disorder | P1 | Completed | 47 | RCT, Open-label | RBP-6000, SUBOXONE Sublingual Film |
| NCT00756353 Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED) | Drug Addiction | Completed | 600 | — | — | |
| NCT02136784 Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals | Analgesic Response | N/A | Unknown | 12 | RCT, Single-blind | morphine sulfate, hydrocodone, hydromorphone HCI, oxycodone, buprenorphine, oral tablet placebo, sublingual tablet placebo |
| NCT00723749 Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603) | Opioid-Related Disorders, Opiate Dependence | Completed | 384 | — | Buprenorphine/Naloxone | |
| NCT03604861 An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery | Opioid-use Disorder, Opioid-related Disorders | Completed | 534 | — | — | |
| NCT00725608 Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444) | Opioid-Related Disorders, Opiate Dependence | Completed | 339 | — | buprenorphine/naloxone | |
| NCT00723697 Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED) | Buprenorphine, Naloxone | Completed | 1,307 | — | buprenorphine | |
| NCT04815590 Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose | Opioid-Use Disorder, Opioid Overdose | Unknown | 40 | — | — | |
| NCT00679458 Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine | Pain | N/A | Completed | 12 | RCT, Double-blind | buprenorphine and low-dose naloxone, buprenorphine alone |
| NCT02535494 Risks and Benefits of Naloxone Prescribing | Opioid Overdose | N/A | Completed | 405 | RCT, Single-blind | — |
| NCT05860959 SUBLOCADE Long-term Outcomes | Opioid Use Disorder | Completed | 480 | — | — | |
| NCT05878210 Evaluating the SUBLOCADE Treatment Exit Strategy | Opioid Use Disorder | Completed | 12 | — | — | |
| NCT03752528 Evaluation of Long-term Buprenorphine Plasma Exposure | Opioid-use Disorder | Completed | 53 | — | — | |
| NCT04577144 An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term | Opioid Use Disorder | Terminated | 216 | — | — |